Brussels (Associated Press)-On Friday, the European Medicines Agency approved doctors to take one more dose from each vial of coronavirus vaccine produced by Pfizer-BioNTech. This was combined with the purchase of 300 million additional serum injections. Can speed up the vaccination rate of the 27-nation alliance.
The European Medicines Agency said that its Human Medicines Board recommends updating the product information of the vaccine to clarify that each vial contains six doses instead of the five doses originally recommended when the Pfizer-BioNTech vaccine was approved on December 21
Hanno Kautz, spokesperson for the German Ministry of Health, told reporters in Berlin that this change will take effect immediately, increasing the available vaccine dose by 20%.
Many doctors across the European Union have drawn six doses of vaccine from each vial, and this practice has been allowed in the United States, the United Kingdom and elsewhere.
Pharmaceutical companies regularly put unnecessary vaccines into vials to ensure the minimum dose even if there is spillage.
The news was released shortly after EU executive authorities stated that they had received 300 million additional doses of Pfizer-BioNTech vaccine. European Commission President Ursula von der Lehn said that the new agreement to buy more doses will double the doses ordered by the Group of 27 nations.
The European Commission later elaborated in a statement that it proposed to the member states to purchase another 200 million doses of vaccine, with the option to purchase another 100 million doses.
“This will enable the EU to purchase up to 600 million doses of this vaccine, which is already in use throughout the EU. Additional doses will be available from the second quarter of 2021,” the EU said. Von der Leyen said that 75 million additional doses will be provided in the second quarter, and the remaining doses will be delivered throughout 2021.
Von Delane said that the European Union, combined with the vaccine contract with Moderna, now has the capacity to vaccinate 380 million people, more than 80% of its population.
The EU has signed six vaccine contracts with Moderna, AstraZeneca-Oxford, Sanofi-GSK, Janssen Pharmaceutica NV, Pfizer-BioNTech and CureVac, with a contract dose of up to 2 billion doses. But so far, only Pfizer-BioNTech and Moderna vaccines have been approved for use in the group.
Emer Cooke, Executive Director of EMA, discussed the drug administration’s review of vaccines in an online public meeting. He said that the evaluation process for the third vaccine produced by AstraZeneca will be Completed at the end of January.
She said: “Of course, it depends on the data we receive and the progress of the evaluation.” “Once the application is actually received, we will make an announcement on it.”
Also on Friday, the UK approved a vaccine developed by Moderna, which is the third licensed vaccine in the country.
The British Ministry of Health stated that the vaccine meets the “strict safety, efficacy and quality standards” of the UK regulatory agency.
The UK has ordered 10 million doses of the vaccine, but it is not expected to be delivered before spring. So far, the UK has vaccinated 1.5 million people with Pfizer BioNTech and AstraZeneca Oxford vaccines.
More and more criticisms, especially in Germany, caused the European Commission’s announcement to the European Commission’s decision to let the European Commission handle all EU member states to purchase vaccines. The European Union’s vaccination program started slowly, and some EU member states have quickly blamed the European Commission for not providing the correct dose of vaccine.
The European Union defended its strategy, insisting that the vaccination program has just begun, and expects a large number of deliveries around April.
“We are facing a situation of strong demand, but production capacity has not kept up. Now, we have taken a positive step forward.” Von Delane said.
After Germany received an additional dose from BioNTech, a German company outside of the EU, von der Leyen made it clear that individual negotiations would violate the agreement accepted by all EU member states.
She said: “We all agree that it is legally binding, there will be no parallel negotiations, no parallel contracts.” “So, the framework that all of us are using is the 27 framework. We negotiate together, and we will conduct negotiations together. Purchase and jointly promote this vaccination process.”
But Kautz said that the deal with BioNTech “is in line with the EU agreement. The additional funding we receive will not break other contracts.”
“This is the prerequisite for us to conclude a memorandum of understanding,” Kautz told reporters in Berlin. “Delivery will not be affected. For example, just because Germany has received additional doses of vaccines or promised increased doses of vaccines, other EU member states will no longer obtain vaccines from BioNTech.”
Kautz made it clear that the 30 million doses of bilateral guarantees will be delivered after ordering through the EU, although they are still expected to be available this year.
Corder reports from The Hague, Netherlands. Geir Moulson and Frank Jordans are from Berlin.
Follow AP reports on https://apnews.com/hub/coronavirus-pandemic, Https://apnews.com/hub/coronavirus-vaccine And https://apnews.com/UnderstandingtheOutbreak